Immunovant, Inc. Common Stock vs. Sutro Biopharma, Inc.
Immunovant, Inc. Common Stock and Sutro Biopharma, Inc. are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| IMVT | STRO | |
|---|---|---|
| Market Cap | $8.25 billion | $420.56 million |
| Revenue (TTM) | — | $99.61 million |
| Net Income (TTM) | — | $-153,602,000 |
IMVT leads on 1 of 1 size & scale factors.
Valuation
| IMVT | STRO | |
|---|---|---|
| Price / Book | — | -6.29 |
| Price / Sales | — | 4.22 |
IMVT and STRO split the valuation factors evenly.
Profitability
| IMVT | STRO | |
|---|---|---|
| Net Margin | — | -154.21% |
| Return on Equity | — | 229.64% |
IMVT and STRO split the profitability factors evenly.
Risk & Sentiment
| IMVT | STRO | |
|---|---|---|
| Short Interest | 0.15% | 0.07% |
STRO leads on 1 of 1 risk & sentiment factors.
Dig deeper: IMVT overview, IMVT financials, STRO overview, STRO financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.